Report · Palestine
Captive Economy
The pharmaceutical industry and the Israeli occupation
by Who Profits Research Center · 2012
About the report
This Who Profits report examines how Israeli and multinational drug companies profit from the occupation’s control over the Palestinian pharmaceutical market.
It shows how the Paris Protocol and Israeli regulations turned the occupied territory into a captive market: Israeli companies such as Teva, Perrigo, Taro and Dexcel sell freely, without the checkpoint delays and extra costs that Palestinian producers face, while Palestinian manufacturers face obstacles selling in East Jerusalem and Israel and struggle to export. Meanwhile public pharmacies, in Gaza especially, suffer chronic shortages of essential drugs.
Read the report? Take the next step.
Join a Palestine solidarity group near you, travel with a delegation to Palestine, or become part of Solidarity Rising.
More reports on Palestine
Share via
Related resources
Erasure & Ecocide: Post 2019, India’s Legal Re-Engineering is Hollowing Out Kashmir’s Rivers and Forests
Tarushi Aswani reports how India's post-2019 legal changes have opened…
Mining in Tibet in 2026: The Copper Boom, Troubled Rivers and the Question of Who Benefits
Tenzin Jigmey examines the copper boom on the Tibetan Plateau, its effects on…
Western Sahara: the law of the strongest returns to the UN
Abdelkader Abderrahmane and Yahia H. Zoubir argue that by yielding to Western…






